Kintsugi Therapeutics
A first-in-class platform
Kintsugi Therapeutics is a preclinical-stage biopharmaceutical Barcelona based company focused on the development of innovative therapies targeting the regulation of endoplasmic reticulum stress for the treatment of liver conditions and other pathologies.
NASH
Non-alcoholic steatohepatitis (NASH) is a common and often clinically silent liver disease that develops as a subgroup of NAFLD characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage.
Discover inhibitorsINHIBITORS
The company’s lead candidate is a first-in-class endoplasmic reticulum stress inhibitor being developed for the treatment of NASH with ongoing proof of concept.
Meet our teamThe team
Meet our team
Carmen Herrero
Co-founder & CEO
Marc Cusachs
Co-founder & COO
Scientific advisory board
Marcin Drag
Scientific Advisor
Matías Antonio Ávila Zaragozá
Scientific Advisor
Manuel Romero-Gómez
Medical Advisor
Manel Puig-Domingo
Medical Advisor
Contact
We’d love to hear from you.
info@kintsugitx.com
Gran Via de les Corts Catalanes, 613, 08007. Barcelona